Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Overdiagnosis in cancer.

Welch HG, Black WC.

J Natl Cancer Inst. 2010 May 5;102(9):605-13. doi: 10.1093/jnci/djq099. Epub 2010 Apr 22. Review.

PMID:
20413742
2.

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.

Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK.

J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99. Review. Erratum in: J Natl Cancer Inst. 2003 Nov 5;95(21):1641.

PMID:
12953083
3.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
4.

Cancer overdiagnosis and overtreatment.

Klotz L.

Curr Opin Urol. 2012 May;22(3):203-9. doi: 10.1097/MOU.0b013e32835259aa. Review.

PMID:
22472510
5.

Prognostic value of serum markers for prostate cancer.

Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P.

Scand J Urol Nephrol Suppl. 2005 May;(216):64-81. Review.

PMID:
16019759
6.

[Active surveillance for screen-detected prostate cancer - a strategy for the future?].

Weissbach L, Schaefer C.

Aktuelle Urol. 2010 Jul;41(4):239-44. doi: 10.1055/s-0030-1247461. Epub 2010 Jul 26. Review. German.

PMID:
20661840
7.

Randomized trial results did not resolve controversies surrounding prostate cancer screening.

Hoffman RM.

Curr Opin Urol. 2010 May;20(3):189-93. doi: 10.1097/MOU.0b013e3283383b55. Review.

PMID:
20224414
8.

Lung cancer screening: improved survival but no reduction in deaths--the role of "overdiagnosis".

Parkin DM, Moss SM.

Cancer. 2000 Dec 1;89(11 Suppl):2369-76. Review.

PMID:
11147614
9.

[Mass screening for detection of prostatic carcinoma].

Bangma CH.

Urologe A. 2000 Jul;39(4):334-40. Review. German.

PMID:
10957775
10.

Should prostate-specific antigen screening be offered to asymptomatic men?

van Vugt HA, Bangma CH, Roobol MJ.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64. Review.

PMID:
20645694
11.

American Cancer Society guideline for the early detection of prostate cancer: update 2010.

Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA; American Cancer Society Prostate Cancer Advisory Committee.

CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98. doi: 10.3322/caac.20066. Epub 2010 Mar 3. Review.

12.

Cancer trends in the United States--a view from Europe.

Quinn MJ.

J Natl Cancer Inst. 2003 Sep 3;95(17):1258-61. Review. No abstract available.

PMID:
12953072
13.

Screening for prostate cancer.

Postma R, Schröder FH.

Eur J Cancer. 2005 Apr;41(6):825-33. Review.

PMID:
15808952
14.

Epidemiology of cancer in the United States.

Cresanta JL.

Prim Care. 1992 Sep;19(3):419-41. Review.

PMID:
1410056
15.

Clarifying uncertainty regarding detection and treatment of early-stage prostate cancer.

Wilt TJ.

Semin Urol Oncol. 2002 Feb;20(1):10-7. Review.

PMID:
11828353
16.

Screening for lung cancer: New horizons?

Rossi A, Maione P, Colantuoni G, Gaizo FD, Guerriero C, Nicolella D, Ferrara C, Gridelli C.

Crit Rev Oncol Hematol. 2005 Dec;56(3):311-20. Epub 2005 Jun 22. Review.

PMID:
15978829
17.

Diagnosis, management and screening of early localised prostate cancer.

Selley S, Donovan J, Faulkner A, Coast J, Gillatt D.

Health Technol Assess. 1997;1(2):i, 1-96. Review.

18.

Screening, early detection, and treatment of prostate cancer: a European view.

Schröder FH.

Urology. 1995 Sep;46(3 Suppl A):62-70. Review.

PMID:
7653022
19.
20.

Active surveillance for prostate cancer: a review.

Klotz L.

Curr Urol Rep. 2010 May;11(3):165-71. doi: 10.1007/s11934-010-0110-z. Review.

PMID:
20425623

Supplemental Content

Support Center